Colchicine Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Colchicine Availability in 2026

Colchicine remains a cornerstone medication across multiple specialties — rheumatology, cardiology, and primary care. But if your patients are reporting difficulty filling prescriptions, you're hearing a real signal. While Colchicine is not on the FDA's official shortage list as of early 2026, supply chain fragility and rising demand have created persistent access challenges that affect patient outcomes.

This briefing covers the current supply landscape, prescribing considerations, cost barriers, and actionable tools you can use to help patients access Colchicine.

Timeline: How We Got Here

Understanding Colchicine's supply dynamics requires context:

• Pre-2009: Colchicine was widely available as an inexpensive, unapproved generic. Patients paid pennies per tablet.
• 2009: FDA approved Colcrys (colchicine 0.6 mg tablets) and granted three-year market exclusivity under the Unapproved Drugs Initiative. All unapproved generic versions were removed from the market.
• 2010-2012: Prices increased approximately 50-fold. Utilization dropped significantly — studies documented a 24% reduction in Colchicine prescriptions among commercially insured patients, with disproportionate impact on FMF patients who require chronic therapy.
• 2014: Mitigare (colchicine 0.6 mg capsule) approved for gout prophylaxis.
• 2019: Gloperba (colchicine 0.6 mg/5 mL oral solution) approved.
• Post-2015: Generic competition gradually returned, but the manufacturing base remained limited compared to pre-2009 levels.
• June 2023: FDA approved Lodoco (colchicine 0.5 mg) for cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease (ASCVD), based on the LoDoCo2 and COLCOT trials showing a 31% reduction in cardiovascular events.
• 2024-2026: Rising cardiovascular prescribing has increased overall Colchicine demand, creating sporadic local stock-outs despite adequate national supply.

Prescribing Implications

Formulation Awareness

When prescribing Colchicine, being explicit about acceptable formulations can help patients fill faster:

• Colchicine 0.6 mg tablets (generic Colcrys) — most commonly dispensed
• Colchicine 0.6 mg capsules (generic Mitigare) — therapeutically equivalent, may be in stock when tablets aren't
• Colchicine 0.6 mg/5 mL oral solution (Gloperba) — less commonly stocked but available
• Colchicine 0.5 mg tablets (Lodoco) — specifically indicated for ASCVD risk reduction

Adding "may substitute capsule for tablet" or prescribing generically allows the pharmacist more flexibility.

Drug Interaction Vigilance

Colchicine's narrow therapeutic index makes drug interactions clinically consequential. Key interactions to review before prescribing:

• Contraindicated combinations (in renal/hepatic impairment): Strong CYP3A4 inhibitors and/or P-glycoprotein inhibitors — Clarithromycin (fatal interactions documented), Ketoconazole, Itraconazole, HIV protease inhibitors (Ritonavir, Atazanavir)
• Dose reduction required: Moderate CYP3A4 inhibitors — Diltiazem, Verapamil, Fluconazole, Erythromycin, Amiodarone
• Increased myotoxicity risk: Statins (particularly with renal impairment), Cyclosporine, Fibrates
• Food interaction: Grapefruit juice (CYP3A4 inhibition)

For patients on multiple interacting medications, consider alternatives. For a comprehensive reference, see our Colchicine drug interactions guide.

Renal and Hepatic Dosing

Dose adjustments are essential for patients with CrCl below 80 mL/min. In severe renal impairment (CrCl <30 mL/min), most interacting drug combinations become contraindicated. Patients with both renal and hepatic impairment should generally not receive Colchicine with any CYP3A4 or P-gp inhibitor.

The Availability Picture

Colchicine is not technically in shortage, but practical availability is uneven:

• Chain pharmacies may not stock it regularly due to automated just-in-time inventory systems
• Independent pharmacies often have more flexible supplier relationships and can special-order within 24 to 48 hours
• Mail-order pharmacies generally maintain more consistent stock for chronic prescriptions
• Specialty pharmacies may be necessary for complex patients (FMF, transplant patients on concurrent immunosuppression)

Cost and Access Barriers

Cost remains a significant barrier, particularly for uninsured or underinsured patients:

• Retail cash price: $200 to $250 for 30 generic tablets (0.6 mg)
• With discount cards: $8 to $30 for the same supply (GoodRx, SingleCare)
• Brand Colcrys: $300 to $500+ without insurance
• Insurance coverage: Generic Colchicine is typically Tier 2 on most commercial and Medicare formularies. Brand-name products may require prior authorization.

Counsel patients to use free discount cards if paying out of pocket — the savings can be over 90%. Many patients are unaware these exist.

Patient Assistance Programs

• Takeda Help at Hand: Provides free Colcrys to eligible uninsured/underinsured patients
• Prescription Hope: Colchicine for $70/month regardless of insurance status
• NeedyMeds and RxAssist: Comprehensive databases of available assistance programs

Tools and Resources for Your Practice

Consider integrating these resources into your workflow:

• Medfinder for Providers: Real-time pharmacy stock search that you can use during the visit or recommend to patients
• GoodRx/SingleCare: Free discount card programs patients can use at any pharmacy
• Formulary lookup tools: Verify coverage before prescribing to minimize fill delays

Directing patients to medfinder.com/providers at the point of prescribing can significantly reduce the callback burden from patients unable to fill.

Looking Ahead

Several trends will shape Colchicine availability going forward:

• Expanding cardiovascular use: As more cardiologists adopt Lodoco based on COLCOT and LoDoCo2 data, demand will continue increasing
• Generic manufacturing expansion: Additional ANDA approvals may broaden the manufacturing base
• Biosimilar/generic pipeline: No biosimilar concerns (small molecule), but new generic entrants could ease supply pressure

For now, proactive prescribing — including formulation flexibility, interaction screening, and connecting patients with availability tools — is the most impactful intervention.

Final Thoughts

Colchicine access challenges in 2026 are manageable but real. The combination of a limited manufacturing base, complex regulatory history, and expanding indications means patients will continue to encounter fill difficulties at certain pharmacies.

As providers, the most effective strategies are: prescribing generically with formulation flexibility, screening for critical drug interactions, connecting patients with Medfinder and discount card resources, and having a short list of therapeutic alternatives ready when Colchicine truly can't be obtained.

For a patient-facing version of this information, see our Colchicine shortage update for patients. For step-by-step guidance on helping patients locate stock, see how to help your patients find Colchicine in stock.